

Catalog No.: RP02779LQ **Recombinant**

Species	Gene ID	Swiss Prot
Mouse	232414	O8BRU4-4

C-hFc

CD370; CLEC9A; 9830005G06Rik;
DNGB-1: HFFF9341: UNO9341

Source HEK293 cells	Purification ≥ 95 % as determined by SDS- PAGE. ≥ 95 % as determined by HPLC.
-------------------------------	---

50.9 kDa 60-70 kDa

< 1 EU/μg of the protein by LAL method.

Supplied as a 0.22 µm filtered solution in PBS, pH 7.4.

 | 400-999-6126

 | cn.market@abclonal.com.cn


 | www.abclonal.com.cn

CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A(+) cells were in close proximity to TUNEL(+) cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.


Recombinant Mouse CLEC9A/CD370 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Lys57-Ile264) of mouse CLEC9A/CD370 (Accession #NP_001192292.1) fused with a hFc tag at the C-terminus.

Store at -70°C. This product is stable at $\leq -70^{\circ}\text{C}$ for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.

Validation Data



Recombinant Mouse CLEC9A/CD370 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



The purity of Mouse CLEC9A is greater than 95% as determined by SEC-HPLC.